In this phase @ , double-blind trial , patients were randomly assigned ( @:@ ) to receive enzalutamide @ mg/day or placebo orally , stratified by ECOG baseline performance status ( @ or @ vs @ ) and mean pain score ( Brief Pain Inventory-Short Form -LSB- BPI-SF -RSB- question @ worst pain , score @ vs @ ) .